BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes

Core Viewpoint - BioPorto A/S has successfully completed a private placement of 25 million new shares, raising a total of DKK 33.5 million to enhance its capital structure and support its focus on in vitro diagnostics for Acute Kidney Injury (AKI) [1][2]. Group 1: Share Capital Increase - The private placement involved issuing 25,000,000 new shares to existing larger shareholders, new professional investors, board members, and the management team [1]. - The gross proceeds from the share issue amount to DKK 33,505,000, with the new shares representing 5.8% of BioPorto's registered share capital prior to the increase [2]. Group 2: Trading and Listing - The new shares will have the same rights as existing shares and will be entitled to dividends from the time the capital increase is registered with the Danish Business Authority [3]. - The shares will be admitted to trading and officially listed on Nasdaq Copenhagen A/S under the Company's permanent ISIN-code (DK0011048619) [3]. Group 3: Company Overview - BioPorto is an in vitro diagnostics company dedicated to improving patient management through actionable biomarkers, particularly focusing on conditions with significant unmet medical needs [5]. - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of Acute Kidney Injury, enabling earlier intervention and tailored patient management strategies [6].